Disruption of Sema3A/Plexin‐A1 inhibitory signalling in oligodendrocytes as a therapeutic strategy to promote remyelination

Disruption of Sema3A/Plexin‐A1 inhibitory signalling in oligodendrocytes as a therapeutic strategy to promote remyelination

Abstract Current treatments in multiple sclerosis (MS) are modulating the inflammatory component of the disease, but no drugs are currently available to repair lesions. Our study identifies in MS patients the overexpression of Plexin‐A1, the signalling receptor of the oligodendrocyte inhibitor Semap...

Full description

Bibliographic Details
Main Authors: Fabien Binamé, Lucas D Pham‐Van, Caroline Spenlé, Valérie Jolivel, Dafni Birmpili, Lionel A Meyer, Laurent Jacob, Laurence Meyer, Ayikoé G Mensah‐Nyagan, Chrystelle Po, Michaël Van der Heyden, Guy Roussel, Dominique Bagnard
Format: Article
Language:English
Published: Wiley 2019-11-01
Series:EMBO Molecular Medicine
Subjects:
multiple sclerosis
myelination
oligodendrocyte
Plexin
Semaphorin
Online Access:https://doi.org/10.15252/emmm.201910378

Internet

https://doi.org/10.15252/emmm.201910378

Similar Items